BSPM A.I CyberSecurity Scoring
28/12/2025
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Boston Scientific Pain Management in 2026.
No incidents recorded for Boston Scientific Pain Management in 2026.
No incidents recorded for Boston Scientific Pain Management in 2026.
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We advance our mission to alleviate pain and improve the quality of life for patients around the world with our innovative products and suite of integrated digital and robotic technologies leverage data, data analytics and artificial intelligence. Founded in 1927 and based in Warsaw, Zimmer Biomet has operations in more than 25 countries and sales in more than 100 countries. We maintain world-class scientific facilities and resources and collaborate with leading clinicians and researchers around the world. Awards and Recognitions • Forbes: America's Best Companies 2026 • Workhuman: Luminary Award 2025 & Innovator Award 2024 • TIME: America's Best Companies [Mid-Size] 2024 • Great Place to Work - Best Workplaces: Switzerland & Poland 2025 • Great Place to Work Certified 2025 - 2026: USA, Poland, India, Colombia, Ireland, Puerto Rico, Kingdom of Saudi Arabia, Switzerland • MedTech: Breakthrough Award Best New Technology Solution in Orthopedics 2025 • Top Employers Institute: China 2025 • VETS Indexes: 4 Star Employer 2025
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 34 countries and territories. The Company's sales reached $12.7 billion in 2024, and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995.
Edwards Lifesciences (NYSE: EW), is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. We thrive on discovery and expanding the boundaries of medical technology, serving patients in 100+ countries, with the help of our employees in areas including Clinical Affairs, Quality Engineering, Research & Development, Regulatory Affairs, Sales & Marketing, corporate functions and more. Contact Us We want to hear from you and engage in meaningful discussions. However, please note that we are not equipped to provide customer, candidate, or technical support through this platform. If you require assistance from those teams, please find their contact information here: https://www.edwards.com/aboutus/contactus If you’re a patient in need of medical advice, please contact your healthcare provider directly. We reserve the right to remove any comments that are off-topic, repetitive, or include hate speech, profanity, or offensive language. Additionally, we will not engage in discussions about competitor products, off-label use of Edwards products, or unsubstantiated/misleading claims that could cause harm. All Terms and Conditions of LinkedIn apply. For the Edwards Lifesciences privacy policy, visit https://www.edwards.com/legal/privacypolicy.
BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com. See community guidelines here: https://tinyurl.com/yunjmzkx.
For nearly a century, we have delivered on our commitment to saving and sustaining the lives of patients, working alongside clinicians and providers around the world. We believe every person — regardless of who they are or where they are from — deserves a chance to live a healthy life, free from illness and full of possibility. At the intersection of progress and purpose is where we are redefining what it means to be a global medtech leader. It is where we are relentlessly pursuing healthcare transformation, fueled by our compassion for patients and providers and the challenges they face. It is where bold ideas meet the promise for meaningful change in the world around us. We are there, at every step of the journey, to help clinicians deliver the best care possible.
Olympus is passionate about creating customer-driven solutions for the medical industry. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 31,000 employees worldwide in nearly 40 countries and regions.
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. For more information, visit www.bostonscientific.com and connect with us on X, Instagram, and Facebook. At Boston Scientific, you will find purpose, a place to grow and opportunities to cultivate your passions. To search and apply for open positions, visit https://bostonscientific.eightfold.ai/careers. You may also review our social media guidelines at http://www.bostonscientific.com/social.
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love to innovate and develop exciting technologies, and we offer competitive salaries and progressive benefits. But it’s our culture - of Care, Collaboration and Courage - that really sets us apart. Through a spirit of ownership and can-do attitude, we work together to win.. We’re a company of people who care about each other, about our customers and their patients, and about our communities. Together, we fulfill our shared purpose of Life Unlimited. Please note: not all products referred to may be approved for use or available in all markets.
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2024 Sales: $22.6 billion ● Industry: Medical Instruments & Supplies ● Employees: 53,000 worldwide ● 44+ Manufacturing and R&D Locations Worldwide ● $1.5 billion spent on research and development in 2024 ● ~14,200 patents owned globally in 2024 ● Products sold in ~75 countries ● Fortune 500 Company ● 9 consecutive years as one a World's Best Workplace Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296
Latest updates, reports, and threat intel affecting the global network.
Boston Scientific has entered an agreement with Siemens Healthineers to push forward commercialisation activities for the latter's AcuNav 4D...
Boston Scientific and the U.S. Food and Drug Administration (FDA) are facing a lawsuit over an allegedly defective spinal cord stimulator,...
Boston Scientific has lifted its fiscal year 2025 (FY25) profit outlook to between $3.02 and $3.04 per share amid continued strong...
Medical device maker Boston Scientific said on Friday it will buy the remaining equity in privately held Nalu Medical for about $533 million...
Acquisition to expand the neuromodulation offerings for people living with chronic pain. MARLBOROUGH, Mass., Oct. 17, 2025 /PRNewswire/...
Medical device maker Boston Scientific said on Friday it will buy the remaining equity in privately held Nalu Medical for about $533 million...
Nalu's implantable neurostimulation system delivers electrical impulses to treat chronic pain originating from the peripheral nerves.
Boston Scientific has acquired Nalu Medical for around $533m, broadening the therapeutic scope of the medtech giant's neuromodulation...
Boston Scientific Corp. said on Friday it will buy the remaining stake in Nalu Medical Inc. it does not already own for about $533 million,...
Craft CMS is a content management system (CMS). In versions 5.0.0-RC1 through 5.9.22 and 4.0.0-RC1 through 4.17.15, an attacker with only a GitHub account can plant a JavaScript payload in a craftcms/cms issue title. When a Craft admin uses the CraftSupport widget’s "Give feedback" screen and types a search term that returns the poisoned issue, the payload executes in the admin’s control panel session. No control panel account or elevated privileges are required on the attacker’s side. This issue has been fixed in versions 4.17.16 and 5.9.23.
Craft CMS is a content management system (CMS). In versions 5.0.0-RC1 through 5.9.21 and 4.0.0-RC1 through 4.17.14, theAssetsController::actionDeleteFolder() only requires the deleteAssets:<volume-uid> permission for the target folder. It never enforces deletePeerAssets:<volume-uid>, even though Assets::deleteFoldersByIds() cascades deletion to every descendant folder and every asset inside, regardless of the uploader's assigned privileges. A low-privilege user who has been granted folder-management rights on a shared volume can therefore destroy assets uploaded by other users (peer assets), bypassing the per-asset peer-permission check that the sibling actionDeleteAsset endpoint correctly applies. This issue has been fixed in versions 4.17.15 and 5.9.22.
Craft CMS is a content management system (CMS). Versions 5.0.0-RC1 through 5.9.20, and 4.0.0-RC1 through 4.17.13 contain an authorization issue in the AssetsController::actionReplaceFile that can delete a source asset without source delete permission by supplying both assetId and sourceAssetId. AssetsController::actionReplaceFile() supports replacing a target asset file using another existing asset as the source. The action loads: assetId -> $assetToReplace and sourceAssetId -> $sourceAsset, then enforces replace permissions using ($assetToReplace ?: $sourceAsset). When both IDs are provided, this expression resolves to the target asset so no permission check is performed against the source asset volume. When both assets are present, Craft copies the source file into the target and then deletes the source asset. There is no deletion check for for the source asset. An authenticated user who can replace files in one volume can delete assets in another volume where they do not have delete permission, as long as they can obtain a sourceAssetId, leading to broken content references and data loss. This issue has been fixed in versions 4.17.14 and 5.9.21.
Description: To issue and renew TLS certificates on behalf of customers, Cloudflare's Universal SSL feature automatically manages the CAA RRset for the customer's zone. This auto-managed RRset is permissive by design (e.g. 'issue "letsencrypt.org"' without parameters). On Universal SSL zones, Cloudflare's authoritative DNS serves this auto-managed RRset at query time, superseding any customer-configured CAA records on the zone. When a customer publishes a stricter CAA record using the RFC 8657 accounturi or validationmethods parameters, the Certificate Authority does not observe those parameters when evaluating the served RRset under RFC 8659. As a result, the RFC 8657 account-binding and validation-method-binding protections are not enforced end-to-end on Universal SSL zones. Successful exploitation could result in issuance of a browser-trusted TLS certificate to an attacker, enabling MITM against the affected domain. Exploitation is non-trivial in practice: an attacker would need to hold an ACME account at one of the Certificate Authorities in the served CAA RRset and to simultaneously satisfy domain control validation across the multiple geographically distinct Network Perspectives the CA relies on for Multi-Perspective Issuance Corroboration. Cloudflare prefixes are anycast-announced from hundreds of locations globally, raising the bar against single-vantage-point BGP hijacks. Any resulting misissuance of a browser-trusted certificate is subject to Certificate Transparency logging required by major browsers, and would be visible to CT monitoring. Mitigation: Customers requiring strict RFC 8657 enforcement need to disable Universal SSL on the affected zone. Universal SSL's automatic CAA management and customer-set RFC 8657 accounturi and validationmethods enforcement are mutually exclusive by the nature of the issue, so there is no in-product workaround that preserves both. Certificate Transparency monitoring is recommended for all customers as a general detection control. Credits: David Osipov (ORCID: https://orcid.org/0009-0005-2713-9242), independent researcher
Out of bounds read and write in Tint in Google Chrome prior to 150.0.7871.46 allowed a remote attacker to potentially perform out of bounds memory access via a crafted HTML page. (Chromium security severity: High)
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.